{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination is proposed to increase tumor immunogenicity and improve anti-PD-L1 responses by expanding antigen presentation on MHC-I.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "The report notes that some mechanistic readouts were strongest in specific model systems, so effects may not be uniform across tumors."
    },
    {
      "claim_id": "C02",
      "claim": "mRNA vaccination induces higher type I interferon activity in tumors than comparator conditions in the mouse experiments.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        },
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        }
      ],
      "caveat": "The table summarizes these values, and the report does not provide additional design details for each numerical comparison in this extract."
    },
    {
      "claim_id": "C03",
      "claim": "Type I interferon signaling is necessary for the sensitization benefit in preclinical settings, because anti-IFNAR1 blockade abolished the benefit.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "Lipid particle controls lacking mRNA did not reproduce the sensitization effect.",
          "line_ref": "L38"
        }
      ],
      "caveat": "This is a mechanistic inference from preclinical perturbation controls and cannot by itself prove causality in patients."
    },
    {
      "claim_id": "C04",
      "claim": "In the retrospective human cohort, prior SARS-CoV-2 mRNA vaccination was associated with improved survival under ICI treatment compared with no prior vaccination.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "The human analysis is retrospective and non-randomized; residual confounding is likely.",
          "line_ref": "L49"
        }
      ],
      "caveat": "This analysis is retrospective with heterogeneous tumor types and variable vaccination timing, so unmeasured confounding may influence outcomes."
    }
  ]
}
